AS A result of the widespread use of dicumarol in the prevention and treatment of thromboembolism, clinicians have become increasingly interested in the role of prothrombin in blood coagulation.

Thirteen patients with liver disease and an abnormal prothrombin time refractory to vitamin K therapy were studied (Tables 1 and 2). None of the patients were actively bleeding, and none had received ...